| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 464.97% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 05/12/2023 | 464.97% | HC Wainwright & Co. | $7 → $10 | Maintains | Buy |
| 04/19/2023 | 295.48% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 03/22/2023 | 69.49% | Evercore ISI Group | $4 → $3 | Maintains | Outperform |
| 03/22/2023 | 295.48% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 08/10/2022 | 295.48% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 01/24/2022 | 464.97% | B. Riley Securities | $24 → $10 | Maintains | Buy |
| 11/09/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/09/2021 | 1594.92% | Evercore ISI Group | → $30 | Initiates Coverage On | → Outperform |
| 11/09/2021 | 1368.93% | Baird | → $26 | Initiates Coverage On | → Outperform |
What is the target price for MiNK Therapeutics (INKT)?
The latest price target for MiNK Therapeutics (NASDAQ: INKT) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $10.00 expecting INKT to rise to within 12 months (a possible 464.97% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MiNK Therapeutics (INKT)?
The latest analyst rating for MiNK Therapeutics (NASDAQ: INKT) was provided by HC Wainwright & Co., and MiNK Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for MiNK Therapeutics (INKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MiNK Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MiNK Therapeutics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
Is the Analyst Rating MiNK Therapeutics (INKT) correct?
While ratings are subjective and will change, the latest MiNK Therapeutics (INKT) rating was a reiterated with a price target of $0.00 to $10.00. The current price MiNK Therapeutics (INKT) is trading at is $1.77, which is within the analyst's predicted range.